Abbott Labs (ABT)

Sold his holdings a few months ago in order to look for other opportunities. Valuations are a little too excessive for him. He prefers to buy in the 12-13 times earnings range. Doesn’t see growth in this one.

Spun off drug side. It is medical devices and has been one of the most consistent growers over the last decade. Reasonably priced, 2.5% yield.

(A Top Pick Nov 26/12. Up 24.63%.) There was a spin out of Abbvie (ABBV-N) from this company

Bought this because he was looking to increase his exposure to healthcare. Not that expensive. Nice diverse portfolio. Good exposure, both in North America and outside. Could be $42 over 12 months.

(A Top Pick Nov 19/12. Up 25.37%.) Spun off their branded pharmaceutical business last year and he offloaded the AbVie (ABBV-N) component and kept this part that was more focused on medical devices and nutritions. Still likes. Increased their dividend by 57%. Most recent quarter showed that they had made 2 acquisitions on the medical devices side in cataract surgery equipment. 3.2% dividend yield.

Adult and infant nutritionals. Generics, very emerging market focused, diversified. Good earnings growth going forward. Very shareholder friendly. Increasing dividend should attract more shareholders.

(Top Pick Oct 11/12, Up 2.37%) Did well with Abvie as well. He sold ABT.

Sold his holdings before the spinoff of their pharmaceutical side into AbbVie (ABBV-N). They are left with the nutritional, diagnostics and medical devices. Trading at about 14 or 15 times earnings. Growing at 11%-13% per year. Very, very stable company and a great core position in your portfolio.

Diversified healthcare company. Recently spun off their pharmaceutical business. Has some decent growth over the next couple of years. Thinks it can get to $42 over a 12-18 time period.

(A Top Pick Sept 4/12. Up 13.65%.) He would like to add to his holdings when he gets the opportunity.

Just moved up stop loss to $34.90 (200 day moving average). They are in the right space. Nutritional component looks to be just in the beginning of a long term uptrend.

Spun off their branded pharmaceutical business last year so now they have 40% in emerging markets and aiming to take closer to 50% over the next couple of years. Have some nutritional products along with their stents. Likes the product pipeline. Playing the increased demand for healthcare products in emerging markets through their branded generics. Continuing to see improved margins. Very attractive entry point. Yield of 1.6%.

One of the better ways to play pharmaceuticals. Amongst the big Pharmas it is one of the few that actually held up through the big selloff of the patent expiries in the mid-2000. Has a yield of about 2%.

(Top Pick May 17/12, Up 24.24%) He stayed with this and not the spin-out. This is about the best performing part of the market this year. Good dividend growth and very strong balance sheets.

(A Top Pick March 15/12. Up 33.59%.) Excellent stock that has done really well. Dividend yield.